Physician profile
Munira Ward
NPI 1417558990
$3,499.53
in general payments reported to CMS, 2019-2025
17 companies · $3,397 in 2025
The $3,397 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $103 · 2025: $3,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $650.21 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $536.64 | 2025 | Fanapt, Hetlioz |
| Abbvie INC. | $367.68 | 2025 | |
| Janssen Pharmaceuticals, INC | $310.97 | 2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $308.25 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $287.23 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.98 | 2025 | Caplyta |
| Alkermes, INC. | $244.79 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $234.01 | 2025 | Austedo Xr, Uzedy |
| Indivior INC. | $141.08 | 2025 | Sublocade |
| Luye Pharma (USA) Ltd. | $41.51 | 2025 | Erzofri Extended-Release |
| Axsome Therapeutics, INC. | $23.07 | 2025 | Auvelity |
| Lundbeck LLC | $21.50 | 2025 | Rexulti |
| Corium, LLC | $20.82 | 2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $19.01 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.64 | 2025 | Qelbree |
| Tris Pharma INC | $14.14 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munira Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.